Enveric Biosciences, Inc.
ENVB
$1.69
$0.095.63%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -4.14% | -10.24% | 22.30% | -0.03% | -25.20% |
| Depreciation & Amortization | -52.84% | -40.47% | -28.20% | -15.50% | -2.86% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.01% | -8.91% | 10.31% | -2.40% | -33.58% |
| Operating Income | 12.01% | 8.91% | -10.31% | 2.40% | 33.58% |
| Income Before Tax | 11.57% | 8.30% | 1.09% | 5.95% | 38.19% |
| Income Tax Expenses | -- | -- | -70.00% | -76.47% | -76.47% |
| Earnings from Continuing Operations | 11.63% | 8.38% | 1.26% | 6.15% | 38.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.63% | 8.38% | 1.26% | 6.15% | 38.27% |
| EBIT | 12.01% | 8.91% | -10.31% | 2.40% | 33.58% |
| EBITDA | 10.50% | 7.76% | -11.85% | 1.94% | 34.34% |
| EPS Basic | 81.44% | 83.12% | 79.82% | 80.78% | 86.25% |
| Normalized Basic EPS | 86.20% | 86.10% | 80.80% | 80.73% | 86.19% |
| EPS Diluted | 81.44% | 83.12% | 79.82% | 80.78% | 86.25% |
| Normalized Diluted EPS | 86.20% | 86.10% | 80.80% | 80.73% | 86.19% |
| Average Basic Shares Outstanding | 814.50% | 698.93% | 484.94% | 426.71% | 403.75% |
| Average Diluted Shares Outstanding | 814.50% | 698.93% | 484.94% | 426.71% | 403.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |